Antiproliferative drug-eluting stents: Systematic review of the benefits and estimate of economic impact;Stents recubiertos de fármacos antiproliferativos: Revisión sistemática del beneficio y estimación del impacto presupuestario

Revista Espanola de Cardiologia

Volumn 57, Issue 7, 2004, Pages 617-628

  Oliva, Gloria ^a   Espallargues, Mireia ^a   Pons, Juan M V ^a  

^a Dept de Sanitat i Seguretat Social ^*  (Spain)

Author keywords

Angioplasty; Coronary restenosis; Drug release systems; Meta analysis; Stents; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; TICLOPIDINE;

ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; ECONOMIC EVALUATION; FOLLOW UP; HOSPITAL COST; HUMAN; RESTENOSIS; RETROSPECTIVE STUDY; REVIEW; SURGICAL RISK; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 4344565304     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13064187     Document Type: Review

References (39)

1. Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. I: history and development. BMJ 2003;326: 1080-2.
2. Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure. BMJ 2003;326:1137-40.
3. Hernández JM, Goicolea J, Duran JM, Auge JM. Registro Español de Hemodinámica y Cardiología Intervencionista. XII Informe oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2002). Rev Esp Cardiol 2003; 56:1105-18.
4. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-88.
5. Bhargava B, Karthikeyan G, Abizaid AS, Mehran R. New approaches to preventing restenosis. BMJ 2003;327:274-9.
6. Oliva G. Eficacia, efectividad y seguridad de la radiación endovascular coronaria en el tratamiento de la reestenosis postangioplastia: Informe Técnico de la Agència d'Avaluació de Tecnologia i Recerca Médiques (AATRM). Madrid: Consejo Interterritorial del Sistema Nacional de Salud, 1999.
7. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1993;270:2598-601.
8. Resultados del análisis coste-efectividad con Cypher®. Barcelona: Health Outcomes Research Europe, 2002.
9. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
10. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban HE, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
11. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
12. Schofer J, Schlüter M, Gershlick AH, Wijns W, García E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-6.
13. Degertekin M, Regar E, Tanabe K, Smits PC, Van der Giessen WJ, Carlier SG, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003;41:184-9.
14. Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003;107:24-7.
15. Lemos PA, Lee CH, Degertekin M, Saia F, Tanabe K, Arampatzis CA, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003;41:2093-9.
16. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: Six and twelve month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
17. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
18. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, Van der Giessen WJ, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-64.
19. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
20. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-45.
21. De la Fuente LM, Miano J, Mrad J, Penaloza E, Yeung AC, Eury R, et al. Initial results of the Quanam drug eluting stent (QuaDS-QP-2) Registry (BARDDS) in human subjects. Catheter Cardiovasc Interv 2001;53:480-8.
22. Rensing BJ, Vos J, Smits PC, Foley DP, Van den Brand MJ, Van der Giessen WJ, et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 2001;22:2125-30.
23. Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610-3.
24. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107:381-3.
25. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995;92:2333-42.
26. Iniguez RA. La reestenosis coronaria. Un problema no resuelto de la angioplastia coronaria transluminal percutánea. Rev Esp Cardiol 1993;46(Supl 3):85-96.
27. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554-9.
28. Degertekin M, Serruys PW, Tanabe Y, Lee CH, Sousa JE, Colombo A, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation 2003;108:2747-50.
29. Technology Assessment Unit (TAU). An evaluation of drug eluting (coated) stents for percutaneous coronary interventions; what should their role be at the McGill University Health Centre (MUHC)? Montreal: McGill University Health Centre, 2003.
30. Bermejo J, Alfonso F. Resumen de los ensayos clínicos presentados en las Sesiones Científicas de la American Heart Association 2003 (Orlando, Florida, 9-12 de noviembre de 2003). Rev Esp Cardiol 2004;57:60-8.
31. Delgado-Rodríguez M, Sillero-Arenas M. Sesgos en el metaanálisis. Med Clin (Barc) 1999;112:43-50.
32. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43: 1110-5.
33. Gershlick A, De SI, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004;109: 487-93.
34. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004;109:1244-9.
35. American College of Cardiology: Drug-Eluting Stents. Chicago, Illinois. Trends-in-Medicine (revista electrónica) 2003 April (consultado 13/01/2004). Disponible en: http://www.trends.in.medicine.com
36. Bermejo J, Alfonso F, Bosch X. Estudio Deliver. Resumen de los ensayos clínicos presentados en la 52 Sesión Científica del American College of Cardiology (Chicago, EE.UU., 30 de marzo a 2 de abril de 2003). Rev Esp Cardiol 2003;56:601-6.
37. Cardiac Revascularization Therapy 2003. Washington, DC. Trends-in-Medicine (revista electrónica) 2003 February (consultado 20/01/2004). Disponible en: www.trends-in-medicine.com
38. Gerckens G, Buellesfeld L, Mueller R, Staberock M, Selbach G, Schmidt T, et al. Evaluation of a tacrolimus-eluting coronary stent with nanoporous ceramic coating in treatment of native coronary artery lesions: phase I and II of the PRESENT study (abstract 1006-184). Presentado en The 52nd Annual Scientific Session of the American College of Cardiology. Chicago, March 30-April 2, 2003. J Am Coll Cardiol 2003;41:7A.
39. Gómez-Hospital JA, Cequier A, Fernández-Nofrerías E, Mauri J, García del Blanco B, Iraculis E, et al. Tratamiento de la reestenosis intra-stent. Situación actual y perspectivas futuras. Rev Esp Cardiol 1999;52:1130-8.